- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 334KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 79KB)
Siponimod – March 2024
Siponimod: Tablet 1 mg (as hemifumarate); Mayzent®
Last updated
30 May 2025